amondys 45- casimersen injection
(Casimersen)Sarepta Therapeutics, Inc.
4 results
elevidys
(delandistrogene moxeparvovec-rokl)Sarepta Therapeutics, Inc.Usage: ELEVIDYS is indicated for treating Duchenne muscular dystrophy (DMD) in individuals aged 4 and older, including both ambulatory patients with a confirmed DMD gene mutation and non-ambulatory patients. The latter indication is approved under accelerated provisions based on the expression of micro-dystrophin in skeletal muscle.exondys 51
(eteplirsen)Sarepta Therapeutics, Inc.Usage: EXONDYS 51 is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene suitable for exon 51 skipping. Its approval is based on observed increases in dystrophin in skeletal muscle, pending further verification of clinical benefit in ongoing trials.vyondys 53
(golodirsen)Sarepta Therapeutics, Inc.Usage: VYONDYS 53 is indicated for treating Duchenne muscular dystrophy (DMD) in patients with a confirmed DMD gene mutation suitable for exon 53 skipping. Approval is based on increased dystrophin production in skeletal muscle, with continued approval dependent on clinical benefit verification in further trials.